The Adenosinergic Pathway in Non-Small Cell Lung Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 28

PMID 39335114

Authors

Olivier Van Kerkhove

Saartje Verfaillie

Brigitte Maes

Kristof Cuppens

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 and CTLA-4 have revolutionized the systemic treatment of non-small cell lung cancer (NSCLC), achieving impressive results. However, long-term clinical benefits are only seen in a minority of patients. Extensive research is being conducted on novel potential immune checkpoints and the mechanisms underlying ICI resistance. The tumor microenvironment (TME) plays a critical role in modulating the immune response and influencing the efficacy of ICIs. The adenosinergic pathway and extracellular adenosine (eADO) are potential targets to improve the response to ICIs in NSCLC patients. First, this review delves into the adenosinergic pathway and the impact of adenosine within the TME. Second, we provide an overview of relevant preclinical and clinical data on molecules targeting this pathway, particularly focusing on NSCLC.

References

Latini S, Pedata F . Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem. 2001; 79(3):463-84. DOI: 10.1046/j.1471-4159.2001.00607.x. View

Zhang H, Cao Y, Tang J, Wang R . CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway. Biomed Res Int. 2022; 2022:9944847. PMC: 9259339. DOI: 10.1155/2022/9944847. View

Leone R, Sun I, Oh M, Sun I, Wen J, Englert J . Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother. 2018; 67(8):1271-1284. PMC: 11028354. DOI: 10.1007/s00262-018-2186-0. View

Mediavilla-Varela M, Luddy K, Noyes D, Khalil F, Neuger A, Soliman H . Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013; 14(9):860-8. PMC: 3909555. DOI: 10.4161/cbt.25643. View

Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P . Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol. 2022; 12:799455. PMC: 8777268. DOI: 10.3389/fimmu.2021.799455. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Lim E, Bendell J, Falchook G, Bauer T, Drake C, Choe J . Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clin Cancer Res. 2022; 28(22):4871-4884. PMC: 9660540. DOI: 10.1158/1078-0432.CCR-22-0612. View

Wolberg G, Zimmerman T, Hiemstra K, Winston M, Chu L . Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate. Science. 1975; 187(4180):957-9. DOI: 10.1126/science.167434. View

Lupia M, Angiolini F, Bertalot G, Freddi S, Sachsenmeier K, Chisci E . CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. Stem Cell Reports. 2018; 10(4):1412-1425. PMC: 5998305. DOI: 10.1016/j.stemcr.2018.02.009. View

10.

Hao Y, Baker D, Ten Dijke P . TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019; 20(11). PMC: 6600375. DOI: 10.3390/ijms20112767. View

11.

Allard B, Cousineau I, Allard D, Buisseret L, Pommey S, Chrobak P . Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis. Oncoimmunology. 2019; 8(8):1601481. PMC: 6682371. DOI: 10.1080/2162402X.2019.1601481. View

12.

Passaro A, Brahmer J, Antonia S, Mok T, Peters S . Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022; 40(6):598-610. DOI: 10.1200/JCO.21.01845. View

13.

Tang J, Ramis-Cabrer D, Curull V, Wang X, Mateu-Jimenez M, Pijuan L . B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors. Cancers (Basel). 2020; 12(9). PMC: 7564217. DOI: 10.3390/cancers12092644. View

14.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

15.

Horenstein A, Quarona V, Toscani D, Costa F, Chillemi A, Pistoia V . Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. Mol Med. 2016; 22:694-704. PMC: 5135080. DOI: 10.2119/molmed.2016.00198. View

16.

Matsubara N, Kusuhara S, Yamamoto N, Sudo K, Yanagita M, Murayama K . Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study. Cancer Chemother Pharmacol. 2023; 93(4):341-352. PMC: 10950984. DOI: 10.1007/s00280-023-04605-9. View

17.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

18.

Regateiro F, Howie D, Nolan K, Agorogiannis E, Greaves D, Cobbold S . Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β. Eur J Immunol. 2011; 41(10):2955-65. DOI: 10.1002/eji.201141512. View

19.

Bertolini G, Compagno M, Belisario D, Bracci C, Genova T, Mussano F . CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche. Int J Mol Sci. 2022; 23(9). PMC: 9104817. DOI: 10.3390/ijms23095126. View

20.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View